LAMAs were largely prescribed for patients in Turkey who had uncontrolled asthma, older age, obesity, exacerbations, and/or worse lung function.

Patients with COPD had slightly more major adverse cardiovascular events after initiating single-inhaler triple therapy vs a LABA-ICS inhaler.

Verona Pharma’s Ohtuvayre has a solid market entry, but its valuation is high. Read why VRNA stock remains a buy for ...

The remaining treatments were prescribed to smaller proportions of patients, with 19% prescribed a long-acting muscarinic antagonist, 18% prescribed LAMA/LABA, 10% prescribed LAMA/LABA/ICS via a ...

With greater clinical severity, they recommend adding a long-acting muscarinic receptor antagonists (LAMA) to ICS + long-acting b2 agonist (LABA) combination for 'triple therapy'. In even more ...

FF/VI was administered once daily via the Ellipta inhaler. Patients who were taking a LAMA in addition to ICS/LABA therapy (triple therapy) who were randomised to the FF/VI group were able to ...

Metered-dose inhaler budesonide-glycopyrrolate-formoterol (Breztri Aerosphere) was associated with a higher risk of a first ...

For the general exposure, any ICS was defined as at least one prescription for any ICS monotherapy, ICS-LABA (long-acting beta-agonist), ICS-LAMA (long-acting muscarinic-antagonist) or triple therapy ...

Combination meds with an ICS and LABA option to relax and open airways, like Advair (fluticasone with salmeterol) Long-acting muscarinic agonists (LAMA) drugs, including Spiriva Respimat (tiotropium ...